$PAVM
PAVmed Inc. Stock $pavm

$pavm Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000149315224018913 Filed on May 13, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2023 Q1
Revenue	$1.000M	$1.000M	$446.0K
YoY Change	502.41%	124.22%	135.98%
Cost Of Revenue	$1.666M	$1.744M	$1.346M
YoY Change	-1.13%	29.57%	264.77%
Gross Profit	-$666.0K	-$744.0K	-$900.0K
YoY Change	-56.16%	-17.33%	400.0%
Gross Profit Margin	-66.6%	-74.4%	-201.79%
Selling, General & Admin	$11.25M	$10.99M	$14.56M
YoY Change	2.37%	-24.51%	10.07%
% of Gross Profit
Research & Development	$1.641M	$1.941M	$4.439M
YoY Change	-52.7%	-56.27%	-25.17%
% of Gross Profit
Depreciation & Amortization	$305.0K	$586.0K	$727.0K
YoY Change	-59.17%	-19.39%	236.57%
% of Gross Profit
Operating Expenses	$12.89M	$12.93M	$19.00M
YoY Change	-10.84%	-31.93%	-1.47%
Operating Profit	-$13.68M	-$14.04M	-$20.40M
YoY Change	-16.99%	-31.2%	4.84%
Interest Expense	-$467.0K	-$2.107M	-$1.102M
YoY Change	-29.77%	91.2%
% of Operating Profit
Other Income/Expense, Net	-$1.230M	-$4.476M	-$1.813M
YoY Change	-12.64%	146.88%	947.98%
Pretax Income	-$14.91M	-$18.51M	-$22.21M
YoY Change	-16.64%	-16.67%	13.15%
Income Tax
% Of Pretax Income
Net Earnings	-$10.83M	-$15.21M	-$17.93M
YoY Change	-25.52%	-15.16%	6.28%
Net Earnings / Revenue	-1082.7%	-1521.2%	-4020.4%
Basic Earnings Per Share		-$2.62	-$0.18
Diluted Earnings Per Share	-$1.19	-$2.62	-$0.19
COMMON SHARES
Basic Shares Outstanding	9.432M shares	9.172M shares	98.42M shares
Diluted Shares Outstanding	9.153M shares	8.695M shares	6.473M shares

Balance Sheet

Concept	2024 Q2	2024 Q1	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$27.40M	$27.88M	$52.81M
YoY Change	-33.95%	-47.2%	-22.01%
Cash & Equivalents	$25.50M	$25.54M	$49.28M
Short-Term Investments
Other Short-Term Assets	$1.906M	$1.214M	$1.004M
YoY Change	18.46%	20.92%	-68.65%
Inventory	$687.0K	$410.0K
Prepaid Expenses
Receivables	$219.0K	$67.00K	$27.00K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$30.21M	$29.57M	$53.84M
YoY Change	-29.96%	-45.07%	-24.17%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.331M	$1.595M	$2.255M
YoY Change	-34.37%	-29.27%	-55.05%
Goodwill
YoY Change
Intangibles	$947.0K	$1.052M	$2.940M
YoY Change	-61.11%	-64.22%
Long-Term Investments
YoY Change
Other Assets	$1.157M	$1.147M	$1.079M
YoY Change	7.23%	6.3%	55.25%
Total Long-Term Assets	$9.206M	$7.680M	$11.45M
YoY Change	-12.79%	-32.9%	-14.15%
TOTAL ASSETS
Total Short-Term Assets	$30.21M	$29.57M	$53.84M
Total Long-Term Assets	$9.206M	$7.680M	$11.45M
Total Assets	$39.41M	$37.25M	$65.29M
YoY Change	-26.58%	-42.94%	-22.59%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.232M	$1.485M	$1.258M
YoY Change	6.02%	18.04%	-84.72%
Accrued Expenses	$6.789M	$6.657M	$3.724M
YoY Change	37.26%	78.76%	6.46%
Deferred Revenue
YoY Change
Short-Term Debt	$44.00M	$45.54M	$45.56M
YoY Change	-0.94%	-0.05%	5119.24%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$53.39M	$55.02M	$50.55M
YoY Change	5.13%	8.84%	188.95%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$4.665M	$2.814M	$3.936M
YoY Change	25.13%	-28.51%	86.72%
Total Long-Term Liabilities	$4.665M	$2.814M	$3.936M
YoY Change	25.13%	-28.51%	86.72%
TOTAL LIABILITIES
Total Short-Term Liabilities	$53.39M	$55.02M	$50.55M
Total Long-Term Liabilities	$4.665M	$2.814M	$3.936M
Total Liabilities	$58.06M	$57.83M	$54.48M
YoY Change	6.5%	6.14%	41.87%
SHAREHOLDERS EQUITY
Retained Earnings	-$320.6M	-$309.7M	-$246.2M
YoY Change	22.95%	25.82%
Common Stock	$10.00K	$9.000K	$101.0K
YoY Change	-90.83%	-91.09%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$73.95M	-$68.78M	-$22.06M
YoY Change
Total Liabilities & Shareholders Equity	$39.41M	$37.25M	$65.29M
YoY Change	-26.58%	-42.94%	-22.59%

Cashflow Statement

Concept	2024 Q2	2024 Q1	2023 Q1
OPERATING ACTIVITIES
Net Income	-$10.83M	-$15.21M	-$17.93M
YoY Change	-25.52%	-15.16%	6.28%
Depreciation, Depletion And Amortization	$305.0K	$586.0K	$727.0K
YoY Change	-59.17%	-19.39%	236.57%
Cash From Operating Activities	-$11.66M	-$13.10M	-$16.29M
YoY Change	-8.84%	-19.57%	32.81%
INVESTING ACTIVITIES
Capital Expenditures	$3.000K	$42.00K	$26.00K
YoY Change	-80.0%	61.54%	-104.53%
Acquisitions
YoY Change
Other Investing Activities		$0.00	$1.000M
YoY Change		-100.0%
Cash From Investing Activities	-$3.000K	-$42.00K	$974.0K
YoY Change	-80.0%	-104.31%	-269.69%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	11.62M	$19.05M	$24.85M
YoY Change	1599.12%	-23.35%	7763.61%
NET CHANGE
Cash From Operating Activities	-11.66M	-$13.10M	-$16.29M
Cash From Investing Activities	-3.000K	-$42.00K	$974.0K
Cash From Financing Activities	11.62M	$19.05M	$24.85M
Net Change In Cash	-37.00K	$5.897M	$9.536M
YoY Change	-99.69%	-38.16%	-176.16%
FREE CASH FLOW
Cash From Operating Activities	-$11.66M	-$13.10M	-$16.29M
Capital Expenditures	$3.000K	$42.00K	$26.00K
Free Cash Flow	-$11.66M	-$13.14M	-$16.31M
YoY Change	-8.92%	-19.44%	39.56%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2024Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2024Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2024Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10017
CY2024Q1	dei	City Area Code CityAreaCode	(917)
CY2024Q1	dei	Local Phone Number LocalPhoneNumber	813-1828
CY2024Q1	dei	Amendment Flag AmendmentFlag	false
CY2024Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2024Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001624326
CY2024Q1	PAVM	Loss On Issue And Offering Cost Senior Secured Convertible Note LossOnIssueAndOfferingCostSeniorSecuredConvertibleNote		usd
CY2023Q1	PAVM	Debt Modification Expense DebtModificationExpense		usd
CY2024Q1	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets		usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q1	PAVM	Preferred Stock Dividends Attributable To Non Controlling Interests PreferredStockDividendsAttributableToNonControllingInterests		usd
CY2024Q1	us-gaap	Stock Issued During Period Value Stock Dividend StockIssuedDuringPeriodValueStockDividend		usd
CY2024Q1	PAVM	Stock Issued During The Periof Of New Issue Impact Of Subsidiary Equity Transactions StockIssuedDuringThePeriofOfNewIssueImpactOfSubsidiaryEquityTransactions		usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Dividend StockIssuedDuringPeriodValueStockDividend		usd
CY2023Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures		usd
CY2023Q1	PAVM	Stock Issued During The Periof Of New Issue Impact Of Subsidiary Equity Transactions StockIssuedDuringThePeriofOfNewIssueImpactOfSubsidiaryEquityTransactions		usd
CY2023Q1	us-gaap	Stock Issued During Period Value Treasury Stock Reissued StockIssuedDuringPeriodValueTreasuryStockReissued		usd
CY2024Q1	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets		usd
CY2024Q1	PAVM	Issuance Of Common Stock Installment Settlement Payment IssuanceOfCommonStockInstallmentSettlementPayment		usd
CY2023Q1	PAVM	Amortization Of Common Stock Payment For Vendor Service Agreement AmortizationOfCommonStockPaymentForVendorServiceAgreement		usd
CY2024Q1	PAVM	Loss On Issue And Offering Costs Senior Secured Convertible Note LossOnIssueAndOfferingCostsSeniorSecuredConvertibleNote		usd
CY2024Q1	us-gaap	Proceeds From Sale Of Property Held For Sale ProceedsFromSaleOfPropertyHeldForSale		usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt		usd
CY2023Q1	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt		usd
CY2024Q1	PAVM	Proceeds Majorityowned Subsidiary Common Stock Atthemarket Facility ProceedsMajorityownedSubsidiaryCommonStockAtthemarketFacility		usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
CY2023Q1	PAVM	Deemed Dividend On Subsidiary Preferred Stock Attributable To Noncontrolling Interests DeemedDividendOnSubsidiaryPreferredStockAttributableToNoncontrollingInterests		usd
CY2024Q1	dei	Document Type DocumentType	10-Q
CY2024Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2024Q1	dei	Document Period End Date DocumentPeriodEndDate	2024-03-31
CY2024Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q1	dei	Entity File Number EntityFileNumber	001-37685
CY2024Q1	dei	Entity Registrant Name EntityRegistrantName	PAVMED INC.
CY2024Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2024Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-1214177
CY2024Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	360 Madison Avenue
CY2024Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	25th Floor
CY2024Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
CY2024Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2024Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024Q1	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	9431721	shares
CY2024Q1	us-gaap	Cost Of Revenue CostOfRevenue	1744000	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	1346000	usd
CY2024Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	4311000	usd
CY2023Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	4539000	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6678000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10407000	usd
CY2024Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	372000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	505000	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1941000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4050000	usd
CY2024Q1	us-gaap	Costs And Expenses CostsAndExpenses	15046000	usd
CY2023Q1	us-gaap	Costs And Expenses CostsAndExpenses	20847000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-14036000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-20401000	usd
CY2024Q1	us-gaap	Interest Income Operating InterestIncomeOperating	72000	usd
CY2023Q1	us-gaap	Interest Income Operating InterestIncomeOperating	121000	usd
CY2024Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	16000	usd
CY2023Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	183000	usd
CY2024Q1	PAVM	Change In Fair Value Senior Secured Convertible Note ChangeInFairValueSeniorSecuredConvertibleNote	2163000	usd
CY2023Q1	PAVM	Change In Fair Value Senior Secured Convertible Note ChangeInFairValueSeniorSecuredConvertibleNote	1040000	usd
CY2023Q1	PAVM	Loss On Issue And Offering Cost Senior Secured Convertible Note LossOnIssueAndOfferingCostSeniorSecuredConvertibleNote	1186000	usd
CY2024Q1	us-gaap	Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost	-369000	usd
CY2023Q1	us-gaap	Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost	-525000	usd
CY2024Q1	PAVM	Debt Modification Expense DebtModificationExpense	-2000000	usd
CY2023Q1	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	1000000	usd
CY2024Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4476000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1813000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-18512000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-22214000	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	-18512000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-22214000	usd
CY2024Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-3300000	usd
CY2023Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-4283000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-15212000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-17931000	usd
CY2024Q1	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	80000	usd
CY2023Q1	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	74000	usd
CY2024Q1	PAVM	Preferred Stock Dividends Attributable To Non Controlling Interests PreferredStockDividendsAttributableToNonControllingInterests	7496000	usd
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-22788000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-18005000	usd
CY2023Q1	us-gaap	Other Noncash Expense OtherNoncashExpense	79000	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.62
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.62
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.78
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.78
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8694904	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8694904	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6473010	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6473010	shares
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-24018000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	495000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	307000	usd
CY2024Q1	PAVM	Issue Common Stock Upon Partial Conversions Of Majority Owned Subsidiary Common Senior Secured Convertible Note IssueCommonStockUponPartialConversionsOfMajorityOwnedSubsidiaryCommonSeniorSecuredConvertibleNote	687000	usd
CY2024Q1	PAVM	Adjustment To Additional Paid In Capital Issue Common Stock Of Majorityowned Subsidiary AdjustmentToAdditionalPaidInCapitalIssueCommonStockOfMajorityownedSubsidiary	4000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	62000	usd
CY2024Q1	PAVM	Purchase Majorityowned Subsidiary Common Stock Employee Stock Purchase Plan PurchaseMajorityownedSubsidiaryCommonStockEmployeeStockPurchasePlan	353000	usd
CY2024Q1	PAVM	Issuance Subsidiary Preferred Stock Series A One IssuanceSubsidiaryPreferredStockSeriesAOne	5670000	usd
CY2024Q1	PAVM	Issuance Of Exchange Subsidiary Preferred Stock Series And Series A One IssuanceOfExchangeSubsidiaryPreferredStockSeriesAndSeriesAOne	-24295000	usd
CY2024Q1	PAVM	Issuance Subsidiary Preferred Stock Series B IssuanceSubsidiaryPreferredStockSeriesB	44285000	usd
CY2024Q1	us-gaap	Noncontrolling Interest Increase From Business Combination NoncontrollingInterestIncreaseFromBusinessCombination	7495000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	934000	usd
CY2024Q1	PAVM	Stockbased Compensation Majorityowned Subsidiary StockbasedCompensationMajorityownedSubsidiary	948000	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	-18512000	usd
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-20575000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	10934000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	10934000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	557000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	2027000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	182000	usd
CY2023Q1	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	276000	usd
CY2023Q1	PAVM	Issuance Majorityowned Subsidiary Common Stock Committed Equity Facility Net Of Deferred Financing Charges IssuanceMajorityownedSubsidiaryCommonStockCommittedEquityFacilityNetOfDeferredFinancingCharges	284000	usd
CY2023Q1	PAVM	Issuance Majorityowned Subsidiary Common Stock Settlement Apardx Installment Payment IssuanceMajorityownedSubsidiaryCommonStockSettlementApardxInstallmentPayment	713000	usd
CY2023Q1	PAVM	Issuance Subsidiary Preferred Stock Series A IssuanceSubsidiaryPreferredStockSeriesA	13625000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	1199000	usd
CY2023Q1	PAVM	Stockbased Compensation Majorityowned Subsidiary StockbasedCompensationMajorityownedSubsidiary	3221000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-22214000	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	10804000	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	10804000	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	-18512000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-22214000	usd
CY2024Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	586000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	727000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1882000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	4419000	usd
CY2023Q1	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	1000000	usd
CY2023Q1	PAVM	Issuance Of Common Stock Installment Settlement Payment IssuanceOfCommonStockInstallmentSettlementPayment	713000	usd
CY2024Q1	PAVM	Amortization Of Common Stock Payment For Vendor Service Agreement AmortizationOfCommonStockPaymentForVendorServiceAgreement	23000	usd
CY2024Q1	PAVM	Change In Fair Value Senior Secured Convertible Note ChangeInFairValueSeniorSecuredConvertibleNote	2163000	usd
CY2023Q1	PAVM	Change In Fair Value Senior Secured Convertible Note ChangeInFairValueSeniorSecuredConvertibleNote	1040000	usd
CY2023Q1	PAVM	Loss On Issue And Offering Costs Senior Secured Convertible Note LossOnIssueAndOfferingCostsSeniorSecuredConvertibleNote	1111000	usd
CY2024Q1	us-gaap	Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost	-369000	usd
CY2023Q1	us-gaap	Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost	-525000	usd
CY2024Q1	us-gaap	Other Noncash Expense OtherNoncashExpense	2000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	6000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	10000	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-531000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	326000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-301000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1444000	usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	154000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	18000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13109000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16362000	usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	42000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	26000	usd
CY2023Q1	us-gaap	Proceeds From Sale Of Property Held For Sale ProceedsFromSaleOfPropertyHeldForSale	1000000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-42000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	974000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	18165000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	13625000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	10000000	usd
CY2024Q1	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	322000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	786000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	557000	usd
CY2023Q1	PAVM	Proceeds Majorityowned Subsidiary Common Stock Atthemarket Facility ProceedsMajorityownedSubsidiaryCommonStockAtthemarketFacility	284000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	62000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	182000	usd
CY2024Q1	PAVM	Proceeds Majorityowned Subsidiary Common Stock Employee Stock Purchase Plan ProceedsMajorityownedSubsidiaryCommonStockEmployeeStockPurchasePlan	353000	usd
CY2023Q1	PAVM	Proceeds Majorityowned Subsidiary Common Stock Employee Stock Purchase Plan ProceedsMajorityownedSubsidiaryCommonStockEmployeeStockPurchasePlan	276000	usd
CY2024Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	19048000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	24924000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	5897000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	9536000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	19639000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	39744000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	25536000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	49280000	usd
CY2024Q1	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_804_eus-gaap--NatureOfOperations_zQw3yOSd2Qif" style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 1 — <span id="xdx_826_zX6v6amoOjw9">The Company</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Description of the Business</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PAVmed is structured to be a multi-product life sciences company organized to advance a pipeline of innovative healthcare technologies. Led by a team of highly skilled personnel with a track record of bringing innovative products to market, PAVmed is focused on innovating, developing, acquiring, and commercializing novel products that target unmet medical needs with large addressable market opportunities. Leveraging our corporate structure—a parent company that will establish distinct subsidiaries for each financed asset—we have the flexibility to raise capital at the PAVmed level to fund product development, or to structure financing directly into each subsidiary in a manner tailored to the applicable product, the latter of which is our current strategy given prevailing market conditions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our current focus is multi-fold. We continue to pursue commercial expansion and execution of EsoGuard, which is the flagship product of our majority-owned subsidiary Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”). In addition, through a separate majority-owned subsidiary, Veris Health (“Veris”), we are focused on entering into strategic partnership opportunities with leading academic oncology systems to expand access to the Veris Platform. In terms of other existing products and technologies, we have adopted an incubator-type platform where we are looking to obtain financing on a product-by-product basis as necessary to advance each asset to a meaningful inflection point along its path to commercialization. Finally, as resources permit, we will continue to explore external innovations that fulfill our project selection criteria without limiting ourselves to any target sector, specialty or condition.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q1	us-gaap	Revenues Revenues	1000000.0	usd
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-22800000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13100000	usd
CY2024Q1	PAVM	Working Capital WorkingCapital	-25400000	usd
CY2024Q1	us-gaap	Secured Debt Current SecuredDebtCurrent	45500000	usd
CY2024Q1	us-gaap	Cash Cash	25500000	usd
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84C_eus-gaap--UseOfEstimates_z1ijW0KxpNn8" style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use of Estimates</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In preparing the unaudited condensed consolidated financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and the determination of corresponding carrying value reserve, if any, and liabilities and the disclosure of contingent losses, as of the date of the unaudited condensed consolidated financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Significant estimates in these unaudited condensed consolidated financial statements include those related to the estimated fair value of debt obligations, stock-based equity awards, intangible assets and common stock purchase warrants. Other significant estimates include the estimated incremental borrowing rate, the provision or benefit for income taxes and the corresponding valuation allowance on deferred tax assets. Additionally, management’s assessment of the Company’s ability to continue as a going concern involves the estimation of the amount and timing of future cash inflows and outflows. On an ongoing basis, the Company evaluates its estimates and assumptions. The Company bases its estimates on historical experience and on various other assumptions believed to be reasonable. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 3 — Summary of Significant Accounting Policies</b> - continued</span></p> <p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p>
CY2024Q1	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_842_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zv1myMcCzdK6" style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Reclassifications</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain prior-year amounts have been reclassified to conform to the current year presentation, which includes presenting costs of revenue within operating expenses on the statements of operations, in the unaudited condensed consolidated financial statements and accompanying notes to the unaudited condensed consolidated financial statements. The impact of the reclassifications made to prior year amounts is not material and did not affect net loss.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q1	PAVM	Veris Box Supplies VerisBoxSupplies	258000	usd
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1010000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	446000	usd
CY2024Q1	us-gaap	Cost Of Revenue CostOfRevenue	1744000	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	1346000	usd
CY2024Q1	PAVM	Prepaid Service Providers And Suppliers PrepaidServiceProvidersAndSuppliers	436000	usd
CY2023Q4	PAVM	Prepaid Service Providers And Suppliers PrepaidServiceProvidersAndSuppliers	739000	usd
CY2024Q1	us-gaap	Prepaid Insurance PrepaidInsurance	520000	usd
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	848000	usd
CY2024Q1	us-gaap	Security Deposit SecurityDeposit	2347000	usd
CY2023Q4	us-gaap	Security Deposit SecurityDeposit	2672000	usd
CY2023Q4	PAVM	Veris Box Supplies VerisBoxSupplies	261000	usd
CY2024Q1	PAVM	Prepaid Expense Deposits And Other Assets Current PrepaidExpenseDepositsAndOtherAssetsCurrent	3561000	usd
CY2023Q4	PAVM	Prepaid Expense Deposits And Other Assets Current PrepaidExpenseDepositsAndOtherAssetsCurrent	4520000	usd
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	1374000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	841000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	794000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	624000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	472000	usd
CY2024Q1	PAVM	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	848000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	4953000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	806000	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	4147000	usd
CY2024Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	476000	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	346000	usd
CY2024Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	22000	usd
CY2023Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2473000	usd
CY2024Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y7M6D
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y10M2D
CY2024Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.07875	pure
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.07875	pure
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3886000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4267000	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	4147000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	4525000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1333000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1565000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2814000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2960000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	5375000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	5375000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	4323000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	3951000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1052000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1424000	usd
CY2024Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	372000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	505000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	316000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	421000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	315000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1052000	usd
CY2024Q1	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	45540000	usd
CY2023Q4	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	44200000	usd
CY2024Q1	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	37320000	usd
CY2024Q1	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	45540000	usd
CY2023Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	37683000	usd
CY2023Q4	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	44200000	usd
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	44200000	usd
CY2024Q1	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	363000	usd
CY2024Q1	us-gaap	Debt Instrument Repaid Principal DebtInstrumentRepaidPrincipal	460000	usd
CY2024Q1	PAVM	Debt Instruments Fair Value DebtInstrumentsFairValue	2163000	usd
CY2024Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	45540000	usd
CY2024Q1	PAVM	Other Income Expense Change In Fair Value OtherIncomeExpenseChangeInFairValue	2163000	usd
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	33650000	usd
CY2023Q1	us-gaap	Debt Instrument Issued Principal DebtInstrumentIssuedPrincipal	11111000	usd
CY2023Q1	PAVM	Fair Value Adjustment Issue Date FairValueAdjustmentIssueDate	789000	usd
CY2023Q1	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	1335000	usd
CY2023Q1	us-gaap	Debt Instrument Repaid Principal DebtInstrumentRepaidPrincipal	166000	usd
CY2023Q1	PAVM	Debt Instruments Fair Value DebtInstrumentsFairValue	251000	usd
CY2023Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	44300000	usd
CY2023Q1	PAVM	Other Income Expense Change In Fair Value OtherIncomeExpenseChangeInFairValue	1040000	usd
CY2024Q1	us-gaap	Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost	-369000	usd
CY2023Q1	us-gaap	Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost	-525000	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	66720	shares
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1882000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	4419000	usd
CY2024Q1	PAVM	Stock Issued During Period Share Atm Facilities StockIssuedDuringPeriodShareATMFacilities	133299	shares
CY2024Q1	PAVM	Stock Issued During Period Value Atm Facilities StockIssuedDuringPeriodValueATMFacilities	495000	usd
CY2024Q1	PAVM	Payments For Commissions Percentage PaymentsForCommissionsPercentage	0.03	pure
CY2024Q1	us-gaap	Warrant Exercise Price Decrease WarrantExercisePriceDecrease	0.52
CY2024Q1	us-gaap	Share Price SharePrice	0.37709668
CY2024Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	23.48
CY2023Q4	us-gaap	Minority Interest MinorityInterest	29813000	usd
CY2024Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-3300000	usd
CY2024Q1	PAVM	Impact Of Subsidiary Equity Transactions ImpactOfSubsidiaryEquityTransactions	1734000	usd
CY2024Q1	PAVM	Lucid Diagnostics Proceeds From Issuance Of Preferred Stock Series A One LucidDiagnosticsProceedsFromIssuanceOfPreferredStockSeriesAOne	5670000	usd
CY2024Q1	PAVM	Lucid Diagnostics Exchange Of Preferred Stock Series And Series A One LucidDiagnosticsExchangeOfPreferredStockSeriesAndSeriesAOne	-24295000	usd
CY2024Q1	PAVM	Lucid Diagnostics Proceeds From Issuance Of Preferred Stock Series B LucidDiagnosticsProceedsFromIssuanceOfPreferredStockSeriesB	44285000	usd
CY2024Q1	PAVM	Lucid Diagnostics Deemed Dividend On Preferred Stock LucidDiagnosticsDeemedDividendOnPreferredStock	-7495000	usd
CY2024Q1	PAVM	Adjustments To Additional Paid In Capital Minority Interest Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalMinorityInterestRequisiteServicePeriodRecognitionValue	4000	usd
CY2024Q1	PAVM	Adjustments To Additional Paid In Capital Minority Interest Requisite Service Period Recognition Value Four AdjustmentsToAdditionalPaidInCapitalMinorityInterestRequisiteServicePeriodRecognitionValueFour	353000	usd
CY2024Q1	PAVM	Issue Common Stock Upon Partial Conversions Of Majority Owned Subsidiary Common Senior Secured Convertible Note IssueCommonStockUponPartialConversionsOfMajorityOwnedSubsidiaryCommonSeniorSecuredConvertibleNote	687000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	744000	usd
CY2024Q1	PAVM	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Values AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValues	5000	usd
CY2024Q1	us-gaap	Minority Interest MinorityInterest	48205000	usd
CY2024Q1	PAVM	Fair Value Of Series B Preferred Stock Issued Shares FairValueOfSeriesBPreferredStockIssuedShares	44285000	shares
CY2024Q1	PAVM	Fair Value Of Series B Preferred Stock Issued FairValueOfSeriesBPreferredStockIssued	44285000	usd
CY2024Q1	PAVM	Less Fair Value Related To Newly Issued Series B Preferred Stock Shares LessFairValueRelatedToNewlyIssuedSeriesBPreferredStockShares	12495000	shares
CY2024Q1	PAVM	Less Fair Value Related To Newly Issued Series B Preferred Stock LessFairValueRelatedToNewlyIssuedSeriesBPreferredStock	12495000	usd
CY2024Q1	PAVM	Less Carrying Value Related To Series And Series A1 Preferred Stock Exchanged For Series B Preferred Stock Shares LessCarryingValueRelatedToSeriesAndSeriesA1PreferredStockExchangedForSeriesBPreferredStockShares	24295000	shares
CY2024Q1	PAVM	Less Carrying Value Related To Series And Series A1 Preferred Stock Exchanged For Series B Preferred Stock LessCarryingValueRelatedToSeriesAndSeriesA1PreferredStockExchangedForSeriesBPreferredStock	24295000	usd
CY2024Q1	PAVM	Deemed Dividend Charged To Accumulated Deficit DeemedDividendChargedToAccumulatedDeficit	7495000	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	-18512000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-22214000	usd
CY2024Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-3300000	usd
CY2023Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-4283000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-15212000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-17931000	usd
CY2024Q1	PAVM	Preferred Stock Dividends Series B PreferredStockDividendsSeriesB	-80000	usd
CY2023Q1	PAVM	Preferred Stock Dividends Series B PreferredStockDividendsSeriesB	-74000	usd
CY2024Q1	PAVM	Deemed Dividend On Subsidiary Preferred Stock Attributable To Noncontrolling Interests DeemedDividendOnSubsidiaryPreferredStockAttributableToNoncontrollingInterests	-7496000	usd
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-22788000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-18005000	usd
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8694904	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8694904	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6473010	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6473010	shares
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.62
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.62
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.78
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.78
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2589046	shares
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2141538	shares

Files In Submission

Name	View Source	Status
0001493152-24-018913-index-headers.html	Edgar Link	pending
0001493152-24-018913-index.html	Edgar Link	pending
0001493152-24-018913.txt	Edgar Link	pending
0001493152-24-018913-xbrl.zip	Edgar Link	pending
ex10-4.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pavm-20240331.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
pavm-20240331_cal.xml	Edgar Link	unprocessable
pavm-20240331_def.xml	Edgar Link	unprocessable
pavm-20240331_lab.xml	Edgar Link	unprocessable
pavm-20240331_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PAVM
PAVmed Inc. Stock $pavm

2024 Q2 Form 10-Q Financial Statement

#000149315224018913 Filed on May 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PAVM PAVmed Inc. Stock $pavm

2024 Q2 Form 10-Q Financial Statement

#000149315224018913 Filed on May 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PAVM
PAVmed Inc. Stock $pavm